|1.||Neel, Benjamin G: 5 articles (07/2014 - 06/2004)|
|2.||Olivier, Martin: 5 articles (07/2010 - 03/2007)|
|3.||Kappert, Kai: 4 articles (04/2015 - 02/2005)|
|4.||Kehlet, Henrik: 4 articles (09/2013 - 07/2009)|
|5.||Wildgaard, Kim: 4 articles (09/2013 - 07/2009)|
|6.||Ostman, Arne: 4 articles (01/2013 - 02/2005)|
|7.||Hooft van Huijsduijnen, Rob: 4 articles (01/2012 - 10/2002)|
|8.||Tremblay, Michel L: 4 articles (01/2012 - 01/2009)|
|9.||Tiganis, Tony: 3 articles (07/2014 - 03/2007)|
|10.||Pulido, Rafael: 3 articles (12/2013 - 01/2013)|
01/01/2015 - "Two published clinical studies on previously treated patients (PTPs) and clinical pharmacokinetics have described that the pharmacokinetic parameters are similar, and the safety and efficacy for prevention and treatment for bleeding are also similar to those of standard half-life FVIII products. "
08/01/2006 - "These data indicate that Kogenate is safe and very effective for the treatment of bleeding in PTPs with hemophilia A."
08/01/2006 - "The safety and efficacy of Kogenate, a recombinant factor VIII (rFVIII) preparation for the treatment of bleeding episodes, were studied in a 123-patient meta-analysis population of previously treated patients (PTPs), including 15 enrolled in the registration Phase III trial (PTP-I group), 93 from the post-marketing special investigation (PTP-II group), and 15 from short-term special investigations in surgery or tooth extraction (SI group). "
|2.||Hemophilia A (Haemophilia)
09/01/2013 - "Studies that investigated the development of inhibitors in hemophilia A PTPs who were treated with any type of FVIII concentrate and that included at least 25 patients with follow-up were included in the analysis. "
11/01/2011 - "As a result of the infrequency of inhibitors in previously treated patients (PTPs) with hemophilia A and the small size of available clinical studies, the immunogenicity of factor (F)VIII products has been difficult to assess. "
12/01/2006 - "Given the low rate of inhibitor development in PTPs with hemophilia A, small, non-randomized studies are inadequate to determine the rate of inhibitor development after exposure to novel products. "
09/01/2004 - "To estimate inhibitor incidence separately for previously untreated or minimally treated patients (PUPs) with 1-50 exposure days and PTPs with >50 exposure days, we used haemophilia A incidence and prevalence data and pooled mean annual rFVIII consumption per PUP and PTP from international multicentre prospective clinical trials. "
07/01/2012 - "The incidence of clinically relevant inhibitor formation in patients with severe haemophilia (FVIII activity ≤ 1%) was 1.2% for PTPs. "
08/01/2015 - "The use of the SCS in this patient provided significant lasting pain relief for both complex regional pain syndrome and PTPS. "
08/01/2015 - "We believe that the use of SCS should be considered as a treatment option for patients with PTPS to avoid side effects associated with medications and to provide long-term pain relief."
08/01/2015 - "The objective of this case report is to describe the use of in situ spinal cord stimulator (SCS) for postthoracotomy pain syndrome (PTPS). "
03/01/2015 - "Patients with PTPS described discomfort as pain only (15.1%), neuropathic symptoms only (30.2%) or pain and neuropathic symptoms (54.7%). "
03/01/2015 - "Postthoracotomy pain syndrome (PTPS) is a common complication following thoracic surgery. "
09/01/2011 - "Here we review the interplay between RTKs and PTPs as an emerging mechanism for acquired resistance to RTK-targeted therapies, that may aid in the design of improved therapies to prevent and overcome resistance in treatments for cancer patients."
05/01/2012 - "Crucial issues for future studies include the participation of other PTPs in tissue development and maintenance as well as cancer, and the signaling networks perturbed by PTP inactivation. "
07/23/2015 - "Among these mutated PTPs, PTP receptor T (PTPRT) appears to be the most frequently mutated PTP in human cancers. "
07/23/2015 - "Recent whole-exome sequencing of human cancer genomes reveals that many PTPs are frequently mutated in a variety of cancers. "
01/01/2015 - "Hence, PTPs are potential pharmacological targets for novel drugs being developed in order to treat numerous pathologies including cancer. "
03/01/2014 - "Finally, the therapeutic potential of targeting PTPs for combating insulin resistance and alleviating T2D will be discussed. "
06/04/2004 - "Lack of additive impairment of insulin signaling by PTP1B and LAR suggests that these PTPs have overlapping actions in causing insulin resistance in vivo."
04/24/2001 - "Our data suggest that increased expression and/or activity of LAR or related PTPs in insulin target tissues of obese humans may contribute to the pathogenesis of insulin resistance."
01/01/2001 - "Augmented IR tyr dephosphorylation by protein tyrosine phosphatases (PTPs) may contribute to insulin resistance. "
11/06/2009 - "Type 2 diabetes related insults, such as hyperglycemia, oxidative stress, and insulin resistance disturb the phosphorylation/dephosphorylation equilibrium towards an abnormal augmented phosphorylation of signaling proteins associated with changes in PTPs expression, enzymatic activity and interaction with cellular substrates. "
|1.||Protein Tyrosine Phosphatases
|2.||Factor VIII (Coagulation Factor VIII)
|3.||human F8 protein
|4.||bisperoxo(1,10- phenanthroline)oxovanadate(1- )
|5.||Protein-Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)
|7.||oxodiperoxo(pyridine- 2- carboxylate)vanadate(V)
|9.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|10.||Phosphoric Monoester Hydrolases (Phosphatases)
|1.||Tooth Extraction (Tooth Extractions)